1. Home
  2. UFI vs KZIA Comparison

UFI vs KZIA Comparison

Compare UFI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unifi Inc. New

UFI

Unifi Inc. New

HOLD

Current Price

$3.98

Market Cap

65.9M

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$7.16

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFI
KZIA
Founded
1969
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.9M
74.4M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
UFI
KZIA
Price
$3.98
$7.16
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$17.67
AVG Volume (30 Days)
85.3K
257.7K
Earning Date
02-04-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$559,646,000.00
$1,199,108.00
Revenue This Year
$1.39
N/A
Revenue Next Year
$12.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.96
$2.86
52 Week High
$6.49
$17.40

Technical Indicators

Market Signals
Indicator
UFI
KZIA
Relative Strength Index (RSI) 62.35 45.63
Support Level $3.77 $6.07
Resistance Level $3.99 $7.08
Average True Range (ATR) 0.20 0.83
MACD 0.06 0.08
Stochastic Oscillator 85.44 82.28

Price Performance

Historical Comparison
UFI
KZIA

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: